Week In Review: Menarini And Lummy Announce Novel Drug In-Licensings For China
April 18, 2015 at 15:30 PM EDT
The Lummy-Argos agreement calls for an upfront purchase of $10 million worth of Argos stock by Lummy and the TVM China BioPharma Capital I Fund.
